Steven Kyriakos is the Vice President of Finance and Operations of Navrogen Inc. Prior to Navrogen, he was the Executive Director of Accounting and Finance at Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained at Morphotek, a subsidiary of Eisai, and led its global financial operations. In addition, he has held various operational roles with increasing responsibilities over the course of his tenure at Morphotek including human resources, facilities and government grant management. 

Steve received a B.S. in Accounting from West Chester University. He has successfully undertaken managerial leadership programs at Penn State University and International Business Elite Training programs for the Pharmaceutical Industry.

Prior to Morphotek, he was a Senior Accountant at Liberty Property Trust (REIT) where he managed a 120 project portfolio. He brings over 26  years of accounting and finance experience with an emphasis in startup operations and mergers and acquisitions.